Back to top
more

QIAGEN (QGEN)

(Delayed Data from NYSE)

$36.95 USD

36.95
1,964,098

+0.37 (1.01%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $36.96 +0.01 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Myriad Genetics Unveils New Home DNA Sample Collection Kit

by Zacks Equity Research

Myriad Genetics' (MYGN) home DNA sample collection test kit for its GeneSight Psychotropic test enables physicians to remotely provide treatment options to patients with mental health issues.

Manaswita Ghosh Dutta headshot

3 AI Healthcare Stocks to Ride Out the Coronavirus Resurgence

by Manaswita Ghosh Dutta

Efficient use of data by artificially intelligent applications has put into the spotlight their urgent need in the healthcare domain.

Zacks Equity Research

QIAGEN's (QGEN) Selloff Deal With Thermo Fisher Progresses

by Zacks Equity Research

QIAGEN's (QGEN) acquisition deal with Thermo Fisher receives approval from QIAGEN shareholders.

Zacks Equity Research

LabCorp's Xcellerate Coronavirus Solution to Aid Clinical R&D

by Zacks Equity Research

This solution by LabCorp (LH) takes the idea from Covance's COVID-19 Operational Recovery Team to better understand the necessities.

Zacks Equity Research

Bio-Rad Rides on PCR Test Kits for Coronavirus Amid Cost Woe

by Zacks Equity Research

The uptick in Bio-Rad's (BIO) core PCR and Droplet Digital PCR product revenues is the result of robust demand due to coronavirus testing and related research.

Zacks Equity Research

Myriad Genetics' myPath Melanoma Proved Superior Per New Study

by Zacks Equity Research

Myriad Genetics' (MYGN) myPath Melanoma's accuracy to classify skin lesions, termed as indeterminate by standard pathological review, validated by the latest study.

Zacks Equity Research

Here's Why You Should Hold on to Illumina Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Illumina (ILMN) backed by its focus on partnerships and robust demand for its products.

Zacks Equity Research

5 Stocks Trading Near 52-Week High That Can Scale Higher

by Zacks Equity Research

Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.

Zacks Equity Research

LabCorp Neutralizing Antibody Test to Aid Coronavirus Vaccine R&D

by Zacks Equity Research

The information related to neutralizing antibody test of LabCorp (LH) can also be used for the screening of convalescent plasma for prophylactic and therapeutic use.

Zacks Equity Research

Medtronic's DBS System With BrainSense Technology Gets FDA Nod

by Zacks Equity Research

Medtronic's (MDT) first-of-its-kind Percept PC DBS system with the next-generation BrainSense technology clears FDA hurdle, paving the way for data-driven neurostimulation treatment.